The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).
 
Rui-hua Xu
No Relationships to Disclose
 
Hai-Qiang Mai
No Relationships to Disclose
 
Qiu-Yan Chen
No Relationships to Disclose
 
Dongping Chen
No Relationships to Disclose
 
Chaosu Hu
No Relationships to Disclose
 
Kunyu Yang
No Relationships to Disclose
 
Jiyu Wen
No Relationships to Disclose
 
Jin-Gao Li
No Relationships to Disclose
 
Yingrui Shi
No Relationships to Disclose
 
Feng Jin
No Relationships to Disclose
 
Ruilian Xu
No Relationships to Disclose
 
Jianji Pan
No Relationships to Disclose
 
Shenhong Qu
No Relationships to Disclose
 
Ping Li
No Relationships to Disclose
 
Chunhong Hu
No Relationships to Disclose
 
Yi-Chun Liu
No Relationships to Disclose
 
Yi Jiang
No Relationships to Disclose
 
Xia He
No Relationships to Disclose
 
Hung-Ming Wang
No Relationships to Disclose
 
Wan-Teck Lim
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD Oncology; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Taiho Pharmaceutical